explore -WSS

explore

author：leisure time 2025-10-02 11:10:30 - browse：4525

President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： FDA's naming rule on biosimilars has undermined competition

explore

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

Cytokinetics CEO stresses company can launch heart drug on its own

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Primary care physicians play key roles in Alzheimer's management

Military medical care influenced by rank and race, new study finds

Addiction experts warn against a second 'war on drugs'

entertainment

explore

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Alkermes shareholders re

Case highlights the risks of experimental stem cell therapy

Affirmative action in medical school literally saved lives

Glen Campbell's doctor discusses his public struggle with Alzheimer's

After affirmative action ruling, medical educators look to 'holistic review'

With measles on the rise, a personal story of a devastating disease

As demand for Covid shots wanes, Moderna seeks its next success

Data integrity in scientific journals requires "effort" by publishers, institutions

knowledge

Oprah kicked off a national conversation on obesity. Let's have it

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Venture capitalist Bob Kocher on the state of digital health

Abortion pill case raises question: who can sue the FDA?

When prostate cancer spreads, where it goes matters

Merck drug for rare lung condition set for approval in U.S.

focus

focus

explore

knowledge